A mutation in the common docking domain of ERK2 in a human cancer cell line, which was associated with its constitutive phosphorylation

International Journal of Oncology

Volumn 27, Issue 6, 2005, Pages 1499-1504

  Arvind, Ramanathan ^a   Shimamoto, Hiroaki ^a   Momose, Fumio ^a   Amagasa, Teruo ^a   Omura, Ken ^a   Tsuchida, Nobuo ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Common docking domain; ERK2; Mutation; Sevenmaker; Signal transduction; Squamous cell carcinoma

Indexed keywords

ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE 1;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CELL LINE; COMPARATIVE STUDY; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MISSENSE MUTATION; MOUTH TUMOR; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHOSPHORYLATION; POINT MUTATION; SEQUENCE HOMOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; WESTERN BLOTTING;

AMINO ACID SEQUENCE; BASE SEQUENCE; BINDING SITES; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE; CELL LINE, TUMOR; HUMANS; ISOENZYMES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MOUTH NEOPLASMS; MUTATION, MISSENSE; PHOSPHORYLATION; POINT MUTATION; SEQUENCE HOMOLOGY, AMINO ACID; TRANSFECTION;

EID: 33644831522     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lewis TS, Shapiro PS and Ahn N: Signal transduction through MAP kinase cascades. Adv Cancer Res 74: 49-139,1998.
2. Morrison DK and Davis RJ: Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Ann Rev Cell Dev Biol 19: 91-118,2003.
3. Tanoue T and Nishida E: Molecular recognitions in the MAP kinase cascades. Cell Signaling 15: 455-462, 2003.
4. Cook SJ, Beltman J, Cadwallader KA, McMahon M and McCormick F: Regulation of mitogen-activated protein kinase phosphatase-1 expression by extracellular signal-related kinase-dependent and Ca2+-dependent signal pathways in Rat-1 cells. J Biol Chem 272: 13309-13319,1997.
5. Brondello JM, Brunet A, Pouysségur J and McKenzie FR: The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. J Biol Chem 272: 1368-1376,1997.
6. Farooq A and Zhou MM: Structure and regulation of MAPK phosphatases. Cell Signaling 16: 769-779,2004.
7. Tanoue T, Adachi M, Moriguchi T and Nishida E: A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat Cell Biol 2: 110-116, 2000.
8. Khokhlatchev AV, Canagarajah B, Wilsbacher J, Robinson M, Atkinson M, Goldsmith E and Cobb MH: Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell 93: 605-615, 1998.
9. Yang SH, Yates PR, Whitmarsh AJ, Davis R and Sharrochs AD: The Elk-1 ETS-domain transcription factor contains a mitogenactivated protein kinase targeting motif. Mol Cell Biol 18: 710-720,1998.
10. Roovers K and Assoian RK: Integrating the MAP kinase signal into the Gl phase cell cycle machinery. Bioessays 22: 818-826, 2000.
11. Wong AJ, Bigner SH, Bigner DD, Jubzker KW, Hamilton SR and Vogelstein B: Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84: 6899-6903,1987.
12. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL and Wong AJ: Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55: 5536-5539, 1995.
13. Lynch TJ, Bell DW, Sordella R, et at Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139,2004.
14. Malumbre M and Barbacid M: RAS oncogenes: the first 30 years. Nat Rev Cancer 3: 7-12, 2003.
15. Wellbrock C, Karasarides M and Marais R: The RAF proteins take centre stage. Nat Rev Cell Biol 5: 875-885,2004.
16. Sourvinos G, Tsatsanis C and Spandidos DA: Mechanisms of retrovirus-induced oncogenesis. Foia Biol (Praha) 46: 226-232, 2000.
17. Tsatsanis C and Spandidos DA: Oncogeneic kinase signaling in human neoplasms. Ann NY Acad Sci 1028: 168-175, 2004.
18. Cowley S, Paterson H, Kemp P and Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC 12 differentiation and for transformation of NIH 3T3 cells. Cell 77: 841-852,1994.
19. Bruner D, Oellers N, Szabad J, Biggs WH III, Ziipursky SL and Hafen E: A gain-of-function in Drosophila MAP kinase activates multiple receptor tyrosine kinase signaling pathways. Cell 76: 875-888, 1994.
20. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M and Hoshino R: Constitutive activation of the 41-/43-KDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813-822, 1999.
21. Matsumura K, Iritani A, Enomoto S, Torikata C, Matsuyama S, Kurita A, Kurahashi H and Tsuchida N: Defining a common region of DNA amplification at 22q 11.2-12 in head and neck squamous cell carcinomas by quantitative FISH analysis. Genes Chromosomes Cancer 29: 207-212, 2000.
22. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A and Fusenig NE: Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106: 761-771,1988.
23. Sakai E and Tsuchida N: Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene 7: 927-933, 1992.
24. Davies SP, Reddy H, Caivano M and Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105,2000.
25. Munirajan AK, Mohanprasad BK, Shanmugam G and Tsuchida N: Detection of a rare point mutation at codon 59 and relatively high incidence of H-ras mutation in Indian oral cancer. Int J Oncol 13: 971-974,1998.
26. Mishima K, Inoue K and Hayashi Y: Overexpression of extracellular-signal regulated kinases on oral squamous cell carcinoma. Oral Oncol 38: 468-474,2002.
27. Chu Y, Solki PA, Khosravi-Far R, Der C J and Kelly K: The mitogen-activated kinase phosphotases, PAC1, MKP-1 and MKP-2, have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. I Biol Chem 271:6497-6501,1996.
28. Oh-hora M, Ogata M, Mori Y, Adachi M, Imai K, Kosugi A and Hamaoka T: Direct suppression of TCR-mediated activation of extracellular signal-regulated kinase by leukocyte protein tyrosine phosphatase, a tyrosine-specific phosphatase. J Immunol 163: 1282-1288, 1999.
29. Kim SE, Kim SH and Choi KY: Regulation of Drosphila MKP-3 by Drosphila ERK. Ann NY Acad Sci 1010: 51-61, 2003.
30. Zhan XL and Guan KL: A specific protein-protein interaction accounts for the in vivo substrate selectivity of Ptp3 towards the Fus3 MAP kinase. Genes Dev 13: 2811-2827,1999.
31. Bott CM, Thorneycroft SG and Marshall CJ: The sevenmaker gain-of-function mutation in p42 MAP kinase leads to enhanced signalling and reduced sensitivity to dual-specificity phosphatase action. FEBS Lett 352: 201-205,1994.
32. Fang JY and Richardson BC: The MAPK signaling pathways and colorectal cancer. Lancet Oncol 6: 322-327, 2005.
33. Weber JD, Raben DM, Phillips PJ and Baldassare JJ: Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin Dl in Gl phase. Biochem J 15: 61-68,1997.